Company: NCEL
Filing Date: 2025-03-31
Form Type: 425
Source: 0001213900-25-025889
Chunk: 257

Company: NewcelX Ltd.
Filing Date: 2025-03-31
Form: 425
Chunk 257
---
 million, before deducting offering expenses payable by the Company. The Company currently intends to use the net proceeds from
the offering for expenses relating to the merger with Kadimastem Ltd. (“Kadimastem”), working capital and general corporate
purposes

In addition, NLS has signed a $25 million committed
equity facility agreement. These financings are intended to support the planned merger with Kadimastem, a clinical-stage cell therapy
company specializing in neurodegenerative diseases and diabetes.

Specifically, this funding is intended to facilitate
the merger by enabling the merged company to execute Kadimastem’s phase IIa multi-site clinical trial for Amyotrophic Lateral Sclerosis
(ALS) using AstroRx® and the phase I for the IseltRx for type 1 diabetes patients, which is planned to commence following the merger.

“We are pleased to have secured this capital
on favorable terms, which reflects investor confidence in our vision and the transformative potential of our planned merger with Kadimastem,”
said Alex Zwyer, CEO of NLS. “We believe that with these financial resources in place, we are well-positioned to move forward
with completing the transaction and creating a leading company in the field of regenerative medicine and CNS disorders.”

“We are happy to receive this financing
as a vote of confidence by investors in the planned merger, Kadimastem leadership team and the assets of Kadimastem,” said Ronen Twito, Executive Chairman and CEO of Kadimastem. “We believe the financing package will allow the merged company to initiate
the planned Phase IIa clinical trial for AstroRx® and the Phase 1 clinical trial for IsletRx, paving the way for potentially transformative
treatments in both ALS and diabetes.”

The equity investment and committed equity facility
are intended to strengthen the merged company’s balance sheet and provide the flexibility needed to support the integration process
and future pipeline development following the merger.

This news follows the filing of an amendment to
NLS’s registration statement on Form F-4 (File No. 333-284075) submission with the SEC. The merger with Kadimastem remains subject
to customary closing conditions, including regulatory and shareholder approvals.

The securities described above were issued in
a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the "Securities Act"), and Regulation D
promulgated thereunder and, along with the common